These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 29474167)

  • 1. Editorial: Current Strategies for Drug Discovery Targeting Neurological Autoimmune Diseases.
    Skundric DS
    Cent Nerv Syst Agents Med Chem; 2018 Jan; 18(1):3. PubMed ID: 29474167
    [No Abstract]   [Full Text] [Related]  

  • 2. The Immunoproteasome: An Emerging Target in Cancer and Autoimmune and Neurological Disorders.
    Zerfas BL; Maresh ME; Trader DJ
    J Med Chem; 2020 Mar; 63(5):1841-1858. PubMed ID: 31670954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-Type Channel Druggability at a Crossroads.
    Weiss N; Zamponi GW
    ACS Chem Neurosci; 2019 Mar; 10(3):1124-1126. PubMed ID: 30697997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-33: a potential therapeutic target in autoimmune diseases.
    Wang S; Ding L; Liu SS; Wang C; Leng RX; Chen GM; Fan YG; Pan HF; Ye DQ
    J Investig Med; 2012 Dec; 60(8):1151-6. PubMed ID: 23076162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trial watch: targeting IL-17A shows broad promise in autoimmune diseases.
    Nat Rev Drug Discov; 2010 Dec; 9(12):908. PubMed ID: 21119723
    [No Abstract]   [Full Text] [Related]  

  • 6. K+ channel modulators for the treatment of neurological disorders and autoimmune diseases.
    Wulff H; Zhorov BS
    Chem Rev; 2008 May; 108(5):1744-73. PubMed ID: 18476673
    [No Abstract]   [Full Text] [Related]  

  • 7. Editorial: HSA-based drug development and drug delivery systems.
    Yang F; Liang H
    Curr Pharm Des; 2015; 21(14):1784. PubMed ID: 25837717
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug delivery technologies for autoimmune disease.
    Phillips BE; Giannoukakis N
    Expert Opin Drug Deliv; 2010 Nov; 7(11):1279-89. PubMed ID: 20958218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunomodulator effects of intravenous immunoglobulins in neurological autoimmune diseases].
    Mouthon L; Kaveri SV; Kazatchkine MD
    Rev Neurol (Paris); 1995 Feb; 151(2):91-2. PubMed ID: 7676148
    [No Abstract]   [Full Text] [Related]  

  • 10. Cyclosporine in neurological autoimmune disease.
    Belendiuk G; Solch S
    Clin Neuropharmacol; 1988 Aug; 11(4):291-302. PubMed ID: 3061635
    [No Abstract]   [Full Text] [Related]  

  • 11. Interdisciplinary chemical approaches for neuropathology.
    Ramsay RR; Di Giovanni G
    CNS Neurosci Ther; 2014 Jul; 20(7):571-3. PubMed ID: 24935786
    [No Abstract]   [Full Text] [Related]  

  • 12. Modifying protein misfolding.
    Jones D
    Nat Rev Drug Discov; 2010 Nov; 9(11):825-7. PubMed ID: 21030987
    [No Abstract]   [Full Text] [Related]  

  • 13. Kynurenines and the nervous system: therapeutic perspectives.
    Vécsei L
    J Neural Transm (Vienna); 2012 Feb; 119(2):107. PubMed ID: 22160490
    [No Abstract]   [Full Text] [Related]  

  • 14. Editorial to the special issue on the challenge of histamine and histamine receptor pharmacology and therapeutics in the 21st century.
    Tiligada E
    Pharmacol Res; 2016 Dec; 114():74. PubMed ID: 27744085
    [No Abstract]   [Full Text] [Related]  

  • 15. MicroRNAs as CNS Drug Targets.
    Gurwitz D
    Drug Dev Res; 2016 Nov; 77(7):331-335. PubMed ID: 27569840
    [No Abstract]   [Full Text] [Related]  

  • 16. The long march of antisense.
    Jones D
    Nat Rev Drug Discov; 2011 Jun; 10(6):401-2. PubMed ID: 21629279
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunoinflammatory diseases of the central nervous system - the tale of two cytokines.
    Hofer MJ; Campbell IL
    Br J Pharmacol; 2016 Feb; 173(4):716-28. PubMed ID: 25917268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Editorial overview: Immunomodulation: New insights for future treatments.
    Anderton SM; Fillatreau S
    Curr Opin Pharmacol; 2015 Aug; 23():vii-ix. PubMed ID: 26143969
    [No Abstract]   [Full Text] [Related]  

  • 19. An analysis of FDA-approved drugs for inflammation and autoimmune diseases.
    Kinch MS; Merkel J
    Drug Discov Today; 2015 Aug; 20(8):920-3. PubMed ID: 25701283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologics and postbiologics: novel immunotherapeutics for the induction and maintenance of remission.
    van Eden W; Lisse J; Prakken B; Albani S
    Drug Discov Today; 2010 Jan; 15(1-2):71-7. PubMed ID: 19162218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.